Adding obinutuzumab to ibrutinib enhances depletion of CLL cells in peripheral blood and bone marrow after 1 & 6 months combined therapy initial results from the Bloodwise TAP IciCLLe extension study.
Rawstron, A Munir, T Munoz-Vicente, S Brock, K Yates, F Bishop, R Dalal, S de Tute, R Sheehy, O Pettitt, A
Rawstron, A
Munir, T
Munoz-Vicente, S
Brock, K
Yates, F
Bishop, R
Dalal, S
de Tute, R
Sheehy, O
Pettitt, A
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Adding obinutuzumab to ibrutinib enhances depletion of CLL cells in peripheral blood and bone marrow after 1 & 6 months combined therapy initial results from the Bloodwise TAP IciCLLe extension study. 2017, 102:69-69 Haematologica